Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Rare Disease Pathways to Accelerated Approval
The FDA is approving treatments for orphan diseases at an unprecedented rate. Which in itself is great for rare disease patients who have been waiting for a treatment. However, FDA approval does not equal access, as the reimbursement community is demanding demonstration of value to justify the high cost. Absence of strong confirmatory evidence means no access for some patients. Many times, coverage policies are limiting access based on arbitrary requirements, misunderstanding of the accelerated approval pathway, or worse, no understanding of the disease intended to treat. This process results in sick patients seeking treatment only getting sicker and costing more to treat and provide care. Creative solutions should be discussed and explored to this critical issue.